FindTrial
Sign In

Empagliflozin (oral)

DRUG6 trials

Sponsors

Intarcia Therapeutics, The University of Hong Kong, Erbil Polytechnic University, University of Illinois at Chicago, Abdelrahman Mahmoud

Conditions

AlbuminuriaBioequivalanceDiabetes Mellitus, Type 2HIV (Human Immunodeficiency Virus)Metabolic SyndromeObese DiabeticsObese Patients (BMI ≥ 30 kg/m²)Obesity & Overweight

Phase 2

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Not yet recruitingNCT07175051
University of Illinois at ChicagoAlbuminuria, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Start: 2025-12-31End: 2030-10-31Target: 20Updated: 2025-09-16
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
RecruitingNCT07336797
Abdelrahman MahmoudHIV (Human Immunodeficiency Virus), Metabolic Syndrome, Obesity & Overweight
Start: 2025-09-01End: 2027-12-30Target: 66Updated: 2026-01-13

Phase 3

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
TerminatedNCT03060980
Intarcia TherapeuticsDiabetes Mellitus, Type 2
Start: 2017-03-03End: 2018-01-26Updated: 2019-03-07
Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor
Enrolling by invitationNCT07065357
The University of Hong KongMetabolic Syndrome
Start: 2025-08-13End: 2026-12-31Target: 160Updated: 2025-08-24

Phase 4

The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
CompletedNCT07120828
Erbil Polytechnic UniversityObese Diabetics, Obese Patients (BMI ≥ 30 kg/m²), Type 2 Diabetes
Start: 2025-07-15End: 2026-03-15Updated: 2026-03-17

Unknown Phase

Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions
CompletedNCT07479108
ADIUMBioequivalance
Start: 2024-11-29End: 2024-12-11Updated: 2026-03-18